A human surfactant peptide-elastase inhibitor construct as a treatment for emphysema

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 23, 2010, Pages 10661-10666

  Guarnieri, Frank ^a,b,c   Spencer, Jean L ^d   Lucey, Edgar C ^d   Nugent, Matthew A ^b,d   Stone, Phillip J ^d  

^a Paka Pulmonary Pharmaceuticals   (United States)

^b Boston University   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Lung cancer; Resistant infections; Tuberculosis

Indexed keywords

ELASTASE INHIBITOR; ELASTIN; HEPARIN; LEUKOCYTE ELASTASE; LEUKOCYTE ELASTASE INHIBITOR; SP B1 25; SURFACTANT PROTEIN B; SURFACTANT PROTEIN B [1-25] X1; SURFACTANT PROTEIN B [1-25] X2; TRIPEPTIDE X0; TRIPEPTIDE X1; TRIPEPTIDE X2; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; FEMALE; IMMUNOGENICITY; LUNG EMPHYSEMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; DISEASE MODELS, ANIMAL; EMPHYSEMA; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; PANCREATIC ELASTASE; PEPTIDES; PROTEASE INHIBITORS; SUBSTRATE SPECIFICITY; SURFACE-ACTIVE AGENTS;

RODENTIA; TRIFLUORO;

EID: 77953806007     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1001349107     Document Type: Article

References (43)

1. Gonda I (2006) Systemic delivery of drugs to humans via inhalation. J Aerosol Med 19:47-53.
2. Stone PJ, Lucey EC, Snider GL (1990) Induction and exacerbation of emphysema in hamsters with human neutrophil elastase inactivated reversibly by a peptide boronic acid. Am Rev Respir Dis 141:47-52.
3. Lucey EC, Stone PJ, Christensen TG, Breuer R, Snider GL (1988) An 18-month study of the effects on hamster lungs of intratracheally administered human neutrophil elastase. Exp Lung Res 14:671-686.
4. Ip MP, Kleinerman J, Ranga V, Sorensen J, Powers JC (1981) The effects of small doses of oligopeptide elastase inhibitors on elastase-induced emphysema in hamsters: A dose-response study. Am Rev Respir Dis 124:714-717.
5. Ranga V, Kleinerman J, Ip MP, Sorensen J, Powers JC (1981) Effects of oligopeptide chloromethylketone administered after elastase: Renal toxicity and lack of prevention of experimental emphysema. Am Rev Respir Dis 124:613-618.
6. Lucey EC, Stone PJ, Digenis GA, Snider GL (1991) A polymer-bound elastase inhibitor is effective in preventing human neutrophil elastase-induced emphysema. Ann N Y Acad Sci 624:341-342.
7. Stone PJ, Lucey EC, Noskova D, Digenis GA, Snider GL (1992) Covalently linking a peptidyl carbamate elastase inhibitor to a hydrophilic polymer increases its effectiveness in preventing emphysema and secretory cell metaplasia in the hamster. Am Rev Respir Dis 146:457-461.
8. Wang Z, Baatz JE, Holm BA, Notter RH (2002) Content-dependent activity of lung surfactant protein B in mixtures with lipids. Am J Physiol Lung Cell Mol Physiol 283:L897-L906.
9. Gupta M, Hernández-Juviel JM, Waring AJ, Bruni R, Walther FJ (2000) Comparison of functional efficacy of surfactant protein B analogues in lavaged rats. Eur Respir J 16:1129-1133.
10. Seurynck-Servoss SL, Dohm MT, Barron AE (2006) Effects of including an N-terminal insertion region and arginine-mimetic side chains in helical peptoid analogues of lung surfactant protein B. Biochemistry 45:11809-11818.
11. Revak SD, et al. (1996) Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res 39:715-724.
12. Lal MK, Sinha SK (2008) Surfactant respiratory therapy using Surfaxin/sinapultide. Ther Adv Respir Dis 2:339-344.
13. Spencer JL, Stone PJ, Nugent MA (2006) New insights into the inhibition of human neutrophil elastase by heparin. Biochemistry 45:9104-9120.
14. Morrison JF, Walsh CT (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol 61:201-301.
15. Henderson PJ (1972) A linear equation that describes the steady-state kinetics of enzymes and subcellular particles interacting with tightly bound inhibitors. Biochem J 127:321-333.
16. Segel IH (1993) Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems (John Wiley & Sons, New York).
17. Edwards PD, Bernstein PR (1994) Synthetic inhibitors of elastase. Med Res Rev 14:127-194.
18. Greco WR, Hakala MT (1979) Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors. J Biol Chem 254:12104-12109.
19. Williams JC, Stein RL, Giles RE, Krell RD (1991) Biochemistry and pharmacology of ICI 200,880, a synthetic peptide inhibitor of human neutrophil elastase. Ann N Y Acad Sci 624:230-243.
20. McGowan SE, Stone PJ, Calore JD, Snider GL, Franzblau C (1983) The fate of neutrophil elastase incorporated by human alveolar macrophages. Am Rev Respir Dis 127:449-455. (Pubitemid 13083744)
21. Morris SM, Stone PJ, Snider GL, Albright JT, Franzblau C (1981) Ultrastructural changes in hamster lung four hours to twenty-four days after exposure to elastase. Anat Rec 201:523-535.
22. Raub JA, Mercer RR, Miller FJ, Graham JA, O'Neil JJ (1982) Dose response of elastase-induced emphysema in hamsters. Am Rev Respir Dis 125:432-435.
23. Stone PJ, Calore JD, Snider GL, Franzblau C (1982) Role of alpha-macroglobulin-elastase complexes in the pathogenesis of elastase-induced emphysema in hamsters. J Clin Invest 69:920-931.
24. Werb Z, Gordon S (1975) Elastase secretion by stimulatedmacrophages. Characterization and regulation. J Exp Med 142:361-377.
25. Zaslow MC, et al. (1983) Human neutrophil elastase does not bind to alpha 1-protease inhibitor that has been exposed to activated human neutrophils. Am Rev Respir Dis 128:434-439.
26. Cazzola M, Matera MG (2008) Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 155:291-299.
27. Vento S, Cainelli F, Temesgen Z (2008) Lung infections after cancer chemotherapy. Lancet Oncol 9:982-992.
28. Kidd TJ, et al. (2009) Low rates of Pseudomonas aeruginosa misidentification in cystic fibrosis patients. J Clin Microbiol 47:1503-1509.
29. Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: A systematic review of the evidence from old and recent studies. Crit Care 10:R27.
30. Arnold TM, Forrest GN, Messmer KJ (2007) Polymyxin antibiotics for gram-negative infections. Am J Health Syst Pharm 64:819-826.
31. Dudley MN, Loutit J, Griffith DC (2008) Aerosol antibiotics: Considerations in pharmacological and clinical evaluation. Curr Opin Biotechnol 19:637-643.
32. Michalopoulos A, Kasiakou SK, Falagas ME (2005) The significance of different formulations of aerosolized colistin. Crit Care, 9:417-418 and author reply (2005) 417-418.
33. Michalopoulos A, et al. (2005) Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit Care 9:R53-R59.
34. Kellerman D, et al. (2008) Denufosol: A review of studies with inhaled P2Y(2) agonists that led to phase 3. Pulm Pharmacol Ther 21:600-607. (Pubitemid 351970709)
35. Placido R, et al. (2006) P2X(7) purinergic receptors and extracellular ATP mediate apoptosis of human monocytes/macrophages infected with Mycobacterium tuberculosis reducing the intracellular bacterial viability. Cell Immunol 244:10-18.
36. Wilson KJ, Gilmore JL, Foley J, Lemmon MA, Riese DJ, 2nd (2009) Functional selectivity of EGF family peptide growth factors: Implications for cancer. Pharmacol Ther 122:1-8.
37. Zhou BB, et al. (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10:39-50.
38. Fridman JS, et al. (2007) Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer. Clin Cancer Res 13:1892-1902.
39. Fisher JF, Mobashery S (2006) Recent advances in MMP inhibitor design. Cancer Metastasis Rev 25:115-136. (Pubitemid 43723987)
40. Chen C (2008) Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem 15:2173-2191.
41. Walters EH, Gibson PG, Lasserson TJ, Walters JA (2007) Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 1):CD001385.
42. Scullion JE (2007) The development of anticholinergics in the management of COPD. Int J Chron Obstruct Pulmon Dis 2:33-40.
43. Kario K, Uno H, Shimada K (2008) Sleep-predominant lowering of ambulatory blood pressure by bedtime inhalation of a novel muscarinic M3 receptor antagonist: A new "bronchoantihypertensive" strategy targeting the lung in hypertension with chronic obstructive pulmonary disease. Hypertens Res 31:817-821.